S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

JNJ Johnson and Johnson

153.42

-1.51 (-0.97%)

Last Updated: 12:53:04

Delayed by 15 minutes

Form CERT - Certification by an exchange approving securities for listing

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2025 to Apr 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to Apr 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 23 April 2025 (2 days ago) • Edgar (US Regulatory)

Form PX14A6G - Notice of exempt solicitation submitted by non-management
Wednesday 23 April 2025 (2 days ago) • Edgar (US Regulatory)

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Monday 21 April 2025 (4 days ago) • PR Newswire (US)

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Wednesday 16 April 2025 (1 week ago) • Business Wire

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates
Tuesday 15 April 2025 (1 week ago) • PR Newswire (Canada)

Form 8-K - Current report
Tuesday 15 April 2025 (1 week ago) • Edgar (US Regulatory)

Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
Tuesday 15 April 2025 (1 week ago) • Business Wire

Johnson & Johnson Reports Q1 2025 Results
Tuesday 15 April 2025 (1 week ago) • Business Wire

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
Thursday 10 April 2025 (2 weeks ago) • PR Newswire (US)

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
Tuesday 8 April 2025 (2 weeks ago) • PR Newswire (US)

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
Monday 7 April 2025 (3 weeks ago) • Business Wire

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
Friday 4 April 2025 (3 weeks ago) • PR Newswire (US)

More Johnson and Johnson News Articles

Code Green Apparel (PK)

TPT Global Tech (CE)

CAVU Resources (PK)

UAV Corpoation (PK)

Liquidmetal Technologies (QB)

Accredited Solutions (PK)

1812 Brewing (PK)

VeeMost Technologies (PK)

Digital Brand Media and ... (PK)

Elite Pharmaceuticals (QB)

Kraig Biocraft Laborator... (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions